Aveanna Healthcare Holdings (AVAH) Earnings Date & Reports

Key Takeaways

• Aveanna Healthcare (AVAH) is scheduled to release its second quarter 2026 results before the market opens on Thursday, August 13, 2026, followed by a conference call at 10:00 a.m. Eastern Time.
• Wall Street analysts project consensus earnings per share (EPS) of approximately $0.16 to $0.17 on revenue in the range of $632 million to $648 million for the quarter.
• The company enters this report with strong momentum, having beaten consensus estimates in each of the last several quarters, including a first quarter 2026 EPS of $0.18 that surpassed the $0.13 consensus by nearly 38%.
• Investors will be closely monitoring updates on the Family First Homecare acquisition, which management previously indicated was expected to close late in the second quarter.
• Key operational metrics under scrutiny include Private Duty Services (PDS) hours growth, preferred payer mix expansion, and Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin trends.
• Aveanna raised its full-year 2026 guidance in May to revenue of $2.56 billion to $2.58 billion and Adjusted EBITDA of $328 million to $332 million, setting a high bar for the second half of the year.

Earnings Context and Why It Matters

Aveanna Healthcare's second quarter report carries significant weight for investors assessing the durability of the company's multi-year turnaround. After emerging from a period of margin compression and labor headwinds, Aveanna has delivered a steady cadence of consensus-beating results, driven by expanding preferred payer relationships and disciplined cost management. The stock has rallied more than 140% over the past twelve months, reflecting growing confidence in the company's ability to generate sustainable profitability in the home-based care market. With the pending Family First Homecare acquisition expected to broaden Aveanna's footprint in the private duty nursing space, the Q2 report serves as both a report card on organic execution and a potential milestone for the company's inorganic growth strategy.

Earnings Expectations

Consensus analyst estimates for Aveanna's second quarter of fiscal 2026 point to EPS in the range of $0.16 to $0.17, with revenue expectations clustering between approximately $632 million and $648 million. These figures would represent a slight moderation in earnings per share compared to the $0.18 reported in Q1 2026 but a meaningful year-over-year revenue increase from the $589.6 million recorded in Q2 2025. For context, Aveanna posted Q2 2025 EPS of $0.18 — a quarter that delivered a 350% earnings surprise relative to the then-consensus of $0.04. The company has now topped analyst EPS expectations for at least five consecutive quarters.

Management raised its full-year 2026 guidance alongside the Q1 release, projecting revenue of $2.56 billion to $2.58 billion and Adjusted EBITDA of $328 million to $332 million. Importantly, that guidance excludes any contribution from the Family First acquisition. Investors will be watching for any revision to this outlook, particularly if the acquisition has closed and initial integration metrics are available. Key segment-level metrics to monitor include PDS revenue per hour (which reached $44.43 in Q1, up 5.7% year-over-year), Home Health & Hospice admissions trends, and Medical Solutions revenue per Unique Patient Served (UPS).

AI Screener

For investors seeking to identify earnings-driven opportunities beyond individual stock analysis, Tickeron's AI Screener offers an AI-powered stock and ETF discovery platform designed to streamline market research. The tool enables traders and investors to scan thousands of securities using customizable filters that span technical patterns, fundamental metrics, volatility profiles, trend indicators, and proprietary AI-driven signals. Users can narrow their search by industry, market capitalization, specific technical indicators, price patterns, and performance benchmarks, helping surface trade ideas, breakout candidates, and trending stocks far more efficiently than manual screening methods allow. Exploring the AI Screener can complement traditional earnings analysis by highlighting stocks exhibiting pre- or post-earnings momentum patterns across sectors.

Market Reaction and Investor Sentiment

Investor sentiment heading into Aveanna's Q2 report appears cautiously optimistic but tempered by several cross-currents. The stock closed at $9.75 on July 29, trading roughly 5.5% below its 52-week high of $10.32 and well above its 52-week low of $3.73. Following the Q1 2026 beat on May 14, shares gained approximately 7.8% in the subsequent trading session, reflecting the market's positive reception to the outsized earnings surprise and raised guidance. Analyst consensus currently stands at a "Moderate Buy" rating with an average 12-month price target near $10.56, suggesting room for modest upside from current levels.

Offsetting the broadly favorable fundamental backdrop, elevated insider selling activity has drawn attention. Over the trailing ninety days, insiders have sold more than 31 million shares valued at approximately $215 million, including a large block sale by a major shareholder. While insider selling can occur for reasons unrelated to a company's prospects, the magnitude of recent dispositions may contribute to investor caution ahead of the print. Labor cost inflation and ongoing regulatory scrutiny of the home healthcare industry represent additional risk factors that could influence post-earnings price action.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, several forward-looking themes will shape how investors interpret Aveanna's Q2 report and position for the remainder of 2026.

The status and financial impact of the Family First Homecare acquisition sits at the top of the watch list. When announced in March 2026, management projected the deal would close late in the second quarter with full synergy realization expected by December. Any update on the closing timeline, purchase price adjustments, or early integration progress will be closely parsed. The acquisition is viewed as strategically important for expanding Aveanna's private duty nursing platform in key markets.

Preferred payer penetration remains the central driver of Aveanna's margin recovery story. In Q1 2026, the preferred payer mix within Private Duty Services reached approximately 60% of Managed Care Organization (MCO) volume, up from 57% at year-end 2025, with four new preferred payer wins during the quarter. Management targets eight additional wins for the full year. Continued progress on this front directly supports the spread between revenue per hour and cost of revenue per hour — a critical profitability gauge for the PDS segment.

On the cost side, labor availability and wage inflation continue to present challenges across the home healthcare industry. Aveanna has partially mitigated these pressures through rate increases and wage pass-through provisions in payer contracts, but the balance between caregiver recruitment, retention costs, and reimbursement rates warrants ongoing attention. Additionally, with approximately $1.48 billion in variable-rate debt on the balance sheet, interest rate movements and the company's hedging strategy — which includes interest rate swaps and caps — will influence net income trajectories in the quarters ahead.

Finally, investors should assess the sustainability of Aveanna's recent revenue growth trajectory. First quarter revenue rose 15.9% year-over-year to $647.9 million, and the full-year guidance implies a measured deceleration as the company laps increasingly difficult comparisons from 2025. How management frames the organic growth outlook for the second half of 2026 — particularly within the Home Health & Hospice segment, which delivered 17.4% revenue growth in Q1 — will be an important signal for the stock's valuation multiple going forward.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.